FinlandTuberculosis profile
Population  2015 5.5 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.037 (0.037–0.037) 0.68 (0.67–0.68)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0–0.06)
Incidence  (includes HIV+TB) 0.31 (0.26–0.35) 5.6 (4.8–6.4)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.1 (0.08–0.13)
Incidence (MDR/RR-TB)** 0.017 (<0.01–0.028) 0.31 (0.11–0.51)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.016 (0.012–0.019) 0.1 (0.071–0.14) 0.12 (0.083–0.16)
Males <0.01 (<0.01–<0.01) 0.18 (0.14–0.22) 0.19 (0.15–0.23)
Total 0.021 (0.015–0.027) 0.29 (0.26–0.31) 0.31 (0.26–0.35)
TB case notifications, 2015  
Total cases notified 271
Total new and relapse 267
          - % tested with rapid diagnostics at time of diagnosis 31%
          - % with known HIV status  
          - % pulmonary 76%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.11–0.15)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 4  
          - on antiretroviral therapy 4 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  10
(3–17)
Estimated % of TB cases with MDR/RR-TB 5.1% (2.2–9.8) 0% (0–60)  
% notified tested for rifampicin resistance 84%   219
MDR/RR-TB cases tested for resistance to second-line drugs   8
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 8, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 45% 250
Previously treated cases, excluding relapse, registered in 2014 40% 5
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data